2021
Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use
Wendt FR, Koller D, Pathak GA, Jacoby D, Miller EJ, Polimanti R. Biobank Scale Pharmacogenomics Informs the Genetic Underpinnings of Simvastatin Use. Clinical Pharmacology & Therapeutics 2021, 110: 777-785. PMID: 33837531, PMCID: PMC8376807, DOI: 10.1002/cpt.2260.Peer-Reviewed Original ResearchConceptsLDL-C concentrationsSimvastatin useLow-density lipoprotein cholesterol concentrationsLipoprotein cholesterol concentrationsDrug-metabolizing enzymesElectronic medical recordsStatin therapyStatin treatmentActivity scoreMedical recordsPilot cohortCholesterol concentrationsEuropean ancestry participantsMetabolizer phenotypeClinical decisionNAT2 allelesPolygenic riskNAT2Good responseUK BiobankBiological mechanismsPharmacogenesAssociationPotential benefitsPhenotype
2020
Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients
Schonberger RB, Vallurupalli V, Matlin H, Blitz D, Nwozuzu A, Barron B, Zhang Y, Dai F, Jacoby D, Nasir K, Bardia A. Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients. Preventive Medicine Reports 2020, 18: 101085. PMID: 32368435, PMCID: PMC7190748, DOI: 10.1016/j.pmedr.2020.101085.Peer-Reviewed Original ResearchAmbulatory surgical patientsCardiovascular disease eventsAtherosclerotic cardiovascular diseaseSurgical patientsSecondary preventionCardiovascular diseaseDisease eventsHigh-intensity statin doseLong-term cardiovascular morbidityAtherosclerotic cardiovascular disease eventsMultivariable logistic regression analysisNon-surgical populationUnderuse of statinsTertiary care hospitalRetrospective observational studySubset of patientsPatients age 40High-risk groupLogistic regression analysisAmbulatory surgical centerReferral periodStatin doseStatin underuseCardiovascular morbidityStatin therapy